Navigation Links
Heart Disease Treatment Breakthrough
Date:6/1/2009

GATESHEAD, England, June 1 /PRNewswire/ -- A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the killer disease.

GP Dr Rob Hicks said the launch of Ateronon, the natural supplement developed by Cambridge scientists, was a huge breakthrough in the treatment of heart disease related illnesses that can cause heart attacks and stroke.

Dozens of research studies have shown that lycopene - found in the skins of ripe tomatoes - has the capacity to significantly reduce the build up of plaque in the arteries that can lead to heart attacks and stroke.

Lycopene is the potent antioxidant isolated for its health-promoting properties from the Mediterranean diet (http://www.ateronon.com/).

Until now, scientists have been unable to find a way of modifying lycopene molecules so they can be readily absorbed into the human body.

Researchers from Cambridge Theranostics Limited (CTL), a biotech spin-out company of Cambridge University, have now proved they have done it with their new Ateronon compound.

Dr Hicks said: "If you think that this can reduce the damage to the arteries, which is the damage that ends up causing heart attacks and strokes - this can potentially extend life but also saving lives on a global basis.

"The potential impact is enormous - we might see a fall in the number of people suffering heart attacks, strokes and other problems relating to arterial damage and the clogging up of the arteries. That has to be welcomed," he added.

Results from their early trials involving 150 people with heart disease were made public for the first time at the British Cardiovascular Society annual conference in London on Monday (1st June).

The Ateronon formulation combines lycopene with milk and soy-based proteins to produce a much smaller, and more bio-available molecule. The early studies have shown that Ateronon can inhibit the oxidation of low density lipoprotein (LDL) cholesterol, which can put people at risk of suffereing heart attacks and stroke, to almost zero within eight weeks.

An estimated 17.5 million people died from heart and circulatory diseases in 2005, representing 30% of all global deaths. Of these deaths, an estimated 7.6 million were due to coronary heart disease and 5.7 million were due to stroke[1].

More than 117,000 people die each year in the UK from coronary heart disease. It accounts for one in five deaths in men and one in six deaths in women[2].

The four million people who take statins to help lower their cholesterol and chances of suffering a heart attack or stroke could benefit from using Ateronon. The product can be taken alongside statins.

Although cholesterol does put people at risk of suffering a heart attack or stroke, half of all heart attacks and three quarters of all strokes occur in people who do not have raised cholesterol.

Large scale studies of Ateronon are being undertaken at Addenbrookes Hospital, Cambridge, and at Harvard Medical School, in the expectation that they will demonstrate that the reduction of LDL oxidation is translated into improved heart and circulatory health - and improved survival rates.

The study was built on research originally carried out by the multi-national food giant Nestle, who were looking for a way to capture the therapeutic benefits of the tomato-derived compound lycopene.

After its launch to doctors this month, Ateronon will be made available direct to consumers through high street pharmacists from July onwards.

Dr Gunter Schmidt, a biologist and chief executive of CTL, said he was confident that once doctors had observed the benefits of Ateronon, they would instantly see the potential benefits.

He said: "We are extremely excited about Ateronon. We have 10 worldwide patents recognising its efficacy, but we want its capabilities to be taken very seriously by clinicians as well. We don't want it dismissed as just another food supplement."

For further information go to http://www.ateronon.com or http://www.youtube.com/watch?v=uJjcpnCHOxI

---------------------------------

[1] World Health Organization

[2] British Heart Foundation

For further information, please contact Helen Barklam at Custard Media, tel: +44(0)1772-316924 or +44(0)7917-148900 or email helen@avaandgrace.com.


'/>"/>
SOURCE Ateronon.com
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):